Tuberous
sclerosis, also
known as tuberous sclerosis complex, is a genetic disorder characterized by the
growth of numerous noncancerous (benign) tumors in many parts of the body. It
can occur in the brain, skin, kidneys, and other organs, in some cases leading
to significant health problems. The signs and symptoms of the disease vary from
person to person.
Virtually
all affected people have skin abnormalities, including patches of unusually
light-coloured skin, areas of raised and thickened skin, and growths under the
nails. It can also cause facial angiofibromas, tumors on the face beginning in
childhood. Some affected children have the characteristic features of autism, a
developmental disorder that affects communication and social interaction.
Request
to Get the Sample Pages at:
The drug candidates
of tuberous sclerosis disease pipeline include, but not limited to,
cannabidiol, and TAK-935. Novartis AG, GW Pharmaceuticals plc and Takeda
Pharmaceutical Company Limited are some of the major companies having drugs in
the tuberous sclerosis therapeutics pipeline.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment